Baxter International Inc. (NYSE:BAX) will host its 2012 Investor Conference today in Chicago, and during the conference, the company plans to provide its five-year long-range financial outlook, update investors on its innovation pipeline, and outline the company’s key growth strategies.
Baxter will highlight its ongoing focus on four key growth vectors during presentations by a number of Baxter executives. These vectors of growth include: optimizing the core business portfolio; advancing the company’s new product pipeline; pursuing and accelerating the pace of business development initiatives; and capitalizing on the opportunity to develop new business models, which include public and private partnerships aimed at improving the quality of and access to care in both developed and emerging markets.
''We continue to be encouraged by the strength of our diversified business model, our ability to innovate, our prospects for growth, and the future of our company,'' says Robert L. Parkinson, Jr., chairman and chief executive officer. ''We are focused on specific growth strategies that will enable us to reward shareholders, while meeting the needs of the patients and customers who rely on our products to save and sustain lives.''
Over its five-year long-range plan, Baxter expects to increase sales approximately 5 percent (excluding the impact of foreign currency) and grow earnings per share in the 7 to 9 percent range, both on a compound annual basis. The company also expects to generate cash flow from operations of approximately $4.5 billion by the year 2017. This strong cash flow performance positions the company to continue to reinvest in the business and return significant value to shareholders through dividends and share repurchases.Baxter also will showcase numerous research and development initiatives which continue to advance toward commercialization. The company’s new product pipeline includes numerous products and therapies that address the needs of patients in the acute care setting, as well as the needs of patients with chronic conditions who are increasingly being treated in the home.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts